407 related articles for article (PubMed ID: 34745101)
21. Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients.
Li M; Xia H; Zheng H; Li Y; Liu J; Hu L; Li J; Ding Y; Pu L; Gui Q; Zheng Y; Zhai Z; Xiong S
BMC Cancer; 2019 Nov; 19(1):1084. PubMed ID: 31711453
[TBL] [Abstract][Full Text] [Related]
22. Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings.
Chow A; Phillips M; Siew T; Cull G; Augustson B; Ward M; Joske D
Intern Med J; 2013 Aug; 43(8):932-9. PubMed ID: 23692386
[TBL] [Abstract][Full Text] [Related]
23. An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers.
Liu Y; Sheng L; Hua H; Zhou J; Zhao Y; Wang B
Technol Cancer Res Treat; 2023; 22():15330338231180785. PubMed ID: 37551117
[No Abstract] [Full Text] [Related]
24. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
25. OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma.
Dong H; Wang Q; Zhang G; Li N; Yang M; An Y; Xie L; Li H; Zhang L; Zhu W; Zhao S; Zhang H; Guo X
Cancer Med; 2020 Mar; 9(5):1790-1797. PubMed ID: 31918459
[TBL] [Abstract][Full Text] [Related]
26. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
27. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.
Klanova M; Sehn LH; Bence-Bruckler I; Cavallo F; Jin J; Martelli M; Stewart D; Vitolo U; Zaja F; Zhang Q; Mattiello F; Sellam G; Punnoose EA; Szafer-Glusman E; Bolen CR; Oestergaard MZ; Fingerle-Rowson GR; Nielsen T; Trneny M
Blood; 2019 Feb; 133(9):919-926. PubMed ID: 30617197
[TBL] [Abstract][Full Text] [Related]
28. High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.
Carreras J; Kikuti YY; Hiraiwa S; Miyaoka M; Tomita S; Ikoma H; Ito A; Kondo Y; Itoh J; Roncador G; Martinez A; Colomo L; Hamoudi R; Ando K; Nakamura N
Cancer Sci; 2022 Jan; 113(1):334-348. PubMed ID: 34706126
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients.
Hu M; Wang X; Liu N; Ding K; Zhang G; Liu X
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34109978
[TBL] [Abstract][Full Text] [Related]
31. Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.
Yan J; Yuan W; Zhang J; Li L; Zhang L; Zhang X; Zhang M
Front Endocrinol (Lausanne); 2022; 13():846357. PubMed ID: 35498426
[TBL] [Abstract][Full Text] [Related]
32. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
Keane C; Gill D; Vari F; Cross D; Griffiths L; Gandhi M
Am J Hematol; 2013 Apr; 88(4):273-6. PubMed ID: 23460351
[TBL] [Abstract][Full Text] [Related]
33. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
34. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
Yang Y; Wang L; Ma Y; Han T; Huang M
Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
[TBL] [Abstract][Full Text] [Related]
35. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
[TBL] [Abstract][Full Text] [Related]
36. Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer.
Liu B; Fu T; He P; Du C; Xu K
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34143198
[TBL] [Abstract][Full Text] [Related]
37. Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: Validation of the six-gene predictor score.
Tekin N; Omidvar N; Morris TP; Conget P; Bruna F; Timar B; Gagyi E; Basak R; Naik O; Auewarakul C; Sritana N; Levy D; Cerci JJ; Bydlowski SP; Pereira J; Dimamay MP; Natividad F; Chung JK; Belder N; Kuzu I; Paez D; Dondi M; Carr R; Ozdag H; Padua RA
Oncotarget; 2016 Dec; 7(50):83319-83329. PubMed ID: 27825111
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
39. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
40. Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era.
Sang W; Zhou H; Qin Y; Shen Z; Yan D; Sun C; Song X; Ma Y; Tu D; Bian Z; Nie S; Jin Y; Xu L; Li Z; Xu K
Int J Hematol; 2021 Aug; 114(2):189-198. PubMed ID: 33893987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]